Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Depreciation & Amortization (CF) rose 4597.51% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 3267.11%. This contributed to the annual value of $7.2 million for FY2024, which is 4605.58% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Depreciation & Amortization (CF) is $2.7 million, which was up 4597.51% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $2.7 million in Q3 2025 and a low of $700000.0 during Q1 2021
  • Over the past 5 years, Rocket Pharmaceuticals' median Depreciation & Amortization (CF) value was $1.2 million (recorded in 2023), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Depreciation & Amortization (CF) surged by 60000.0% in 2021, and later surged by 1100.0% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.0 million in 2021, then increased by 5.77% to $1.1 million in 2022, then grew by 26.91% to $1.4 million in 2023, then skyrocketed by 30.52% to $1.8 million in 2024, then skyrocketed by 48.3% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.7 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.5 million in Q1 2025.